Immunic reported a net loss of $34.1 million for the second quarter of 2026, as the company intensified investments in its late-stage multiple sclerosis pipeline. Although the absolute net loss increased year-over-year, the loss per share narrowed significantly due to the increased weighted-average share count following a private placement financing in early 2026.
Key Highlights
- Phase 3 ENSURE-1 and ENSURE-2 trials for vidofludimus calcium in relapsing multiple sclerosis are on track for top-line data readouts by the end of 2026.
- Cash and cash equivalents totaled $155.1 million as of June 30, 2026, which the company expects will fund operations into late 2027.
- Research and development expenses rose to $25.9 million from $21.3 million in the prior year, driven by higher personnel costs and drug-drug interaction studies to support potential regulatory filings.